Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XM22 versus placebo for prevention of chemotherapy-induced neutropenia in advanced non-small cell lung cancer
ISRCTN55761467Phase 3Completed
- Sponsor
- BioGeneriX AG
- Start
- May 2010
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) and chemotherapy-induced neutropenia (CIN) comparing XM22 + cisplatin + etoposide with Placebo + cisplatin + etoposide (2 arms). Primary endpoint: Incidence of febrile neutropenia in cycle 1. Started May 2010; status: completed.
02
Drugs
lipegfilgrastim
03
Conditions
non-small cell lung cancer (NSCLC)chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on ISRCTN55761467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN55761467.